Did psychedelic traditions emerge independently across the world, or are they concentrated in specific cultural contexts? At ICPR 2026, we spoke with anthropologist Manvir Singh about the history of human relationships with psychoactive plants and fungi, indigenous knowledge systems, and the anthropological evidence surrounding psychedelic use.

In 2023, during the 27th Harm Reduction International Conference in Melbourne, Drugreporter visited the North Richmond Medically Supervised Injecting Room (MSIR). We filmed a visit by Helen Clark, former Prime Minister of New Zealand and a member of the Global Commission on Drug Policy, who praised the facility’s life-saving work and called for more services like it across Australia and beyond.

What is consciousness, and what does it tell us about our place in the universe? At ICPR 2026, we spoke with neuroscientist Adam Barrett about panpsychism, altered states of consciousness, the relationship between mind and matter, and how psychedelic experiences challenge conventional assumptions about reality.

What happens after a psychedelic experience? In this Drug Reporter Café interview, coach and educator Márton Mányai explores how integration coaching can help people make sense of their experiences and bring insights into everyday life.

In September 2026, the Norwegian government announced that heroin-assisted treatment now becomes a permanent treatment option in the country. Join us on a visit to Bergen’s HABIB, one of the pilot heroin-assisted treatment programs, to learn how heroin-assisted treatment works in practice!

What happens when an altered state of consciousness becomes part of psychotherapy? We visited a new clinic in Vienna offering ketamine-assisted therapy. Dr. Claus Derganc showed us around and discussed the treatment’s potential, its risks, and how patients work through difficult experiences.

At ICPR 2024, we talked to Jamila Hokanson,from the Yale University School of Medicine, about how psychedelics might offer new hope for people living with obsessive-compulsive disorder (OCD).

At ICPR 2024, we talked to Leonie Schneider and Ian Roullier, co-founders and co-directors of the Psychedelic Participant Advocacy Network (PsyPAN) in the UK, about why patient voices matter in the development of psychedelic therapy.

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researcher Sandeep Nayak about clinical trials, common therapeutic factors, and how the field can better understand the mechanisms behind psychedelic-assisted treatment.

At ICPR 2024, we talked to Robert Jesse, from the Johns Hopkins University, about mystical experiences with psychedelics, their spiritual and cultural dimensions, and the value of community in supporting their responsible integration.